Hematology & Hematologic Malignancies Publications
Hematology Faculty Publications FY24
JULY
1. Tseng NA, Beaudin AE. The impact of prenatal inflammation on hematopoietic development. Curr Opin Hematol. 2023 Jul 1;30(4):130-136. doi: 10.1097/MOH.0000000000000770. PMID: 37254855.
2. López DA, Otsuka KS, Apostol AC, Posada J, Sánchez-Arcila JC, Jensen KD, Beaudin AE. Both maternal IFNγ exposure and acute prenatal infection with Toxoplasma gondii activate fetal hematopoietic stem cells. EMBO J. 2023 Jul 17;42(14):e112693. doi: 10.15252/embj.2022112693. PMID: 37259639; PMCID: PMC10350822.
3. Mercadal S, Gomez CA, Lee CJ, Couriel DR. Infectious complications following CAR-t cell therapy for B cell non-Hodgkin lymphoma: a single-center experience and review of the literature. Ann Hematol. 2023 Jul;102(7):1837-1843. doi: 10.1007/s00277-023-05131-7. PMID: 37246975; PMCID: PMC10225770.
4. Vardell VA, Ermann DA, Fitzgerald LA, Shah HR, Hu B, Stephens DM. Influence of racial and ethnic identity on overall survival in patients with chronic lymphocytic leukemia. Am J Hematol. 2023 Jul;98(7):E172-E174. doi: 10.1002/ajh.26937. PMID: 37078687.
5. Shouse G, Kaempf A, Gordon MJ, Artz A, Yashar D, Sigmund AM, Smilnak G, Bair SM, Mian A, Fitzgerald LA, Bajwa A, Jaglowski S, Bailey N, Shadman M, Patel K, Stephens DM, Kamdar M, Hill BT, Gauthier J, Karmali R, Nastoupil LJ, Kittai AS, Danilov AV. A validated composite comorbidity index predicts outcomes of CAR T-cell therapy in patients with diffuse large B-cell lymphoma. Blood Adv. 2023 Jul 25;7(14):3516-3529. doi: 10.1182/bloodadvances.2022009309. PMID: 36735393; PMCID: PMC10362276.
6. Goda C, Kolovich S, Rudich A, Karunasiri M, Kulkarni R, Rajgolikar G, Neidemire-Colley L, Singh S, Sircar A, Ranganathan P, Garzon R, Sehgal L, Dorrance AM. Epidermal growth factor-like 7 is a novel therapeutic target in mantle cell lymphoma. Exp Hematol. 2023 Jul;123:28-33.e3. doi: 10.1016/j.exphem.2023.05.003. PMID: 37209901.
7. Bindal P, Najjar M, Koehn K, Godara A, Sborov DW, McClune B, Julian K, Wagner C, Mohyuddin GR. Refractoriness to last line of therapy: how often is it mandated and reported? A systematic review of randomized myeloma trials. Leuk Lymphoma. 2023 Jul-Aug;64(7):1340-1343. doi: 10.1080/10428194.2023.2209682. Erratum in: Leuk Lymphoma. 2023 Jun 6;:1. PMID: 37170589.
8. Mohyuddin GR, Kapur R, Costa L. Inclusion criteria of currently enrolling T-cell engaging trials in multiple myeloma: Should we be focusing on lines of prior therapy? Br J Haematol. 2023 Jul;202(1):e1-e2. doi: 10.1111/bjh.18755. PMID: 36916719.
9. Murthy GSG, Kim S, Estrada-Merly N, Abid MB, Aljurf M, Assal A, Badar T, Badawy SM, Ballen K, Beitinjaneh A, Cerny J, Chhabra S, DeFilipp Z, Dholaria B, Perez MAD, Farhan S, Freytes CO, Gale RP, Ganguly S, Gupta V, Grunwald MR, Hamad N, Hildebrandt GC, Inamoto Y, Jain T, Jamy O, Juckett M, Kalaycio M, Krem MM, Lazarus HM, Litzow M, Munker R, Murthy HS, Nathan S, Nishihori T, Ortí G, Patel SS, Van der Poel M, Rizzieri DA, Savani BN, Seo S, Solh M, Verdonck LF, Wirk B, Yared JA, Nakamura R, Oran B, Scott B, Saber W. Association between the choice of the conditioning regimen and outcomes of allogeneic hematopoietic cell transplantation for myelofibrosis. Haematologica. 2023 Jul 1;108(7):1900-1908. doi: 10.3324/haematol.2022.281958. PMID: 36779595; PMCID: PMC10316233.
10. Patel SS, Hong S, Rybicki L, Farlow S, Dabney J, Kalaycio M, Sobecks R, Majhail NS, Hamilton BK. A Pilot Trial of Patient-Reported Outcomes for Acute Graft-Versus-Host-Disease. Transplant Cell Ther. 2023 Jul;29(7):465.e1-465.e7. doi: 10.1016/j.jtct.2023.03.030. PMID: 37003415.
11. Bumma N, Dhakal B, Fraser R, Estrada-Merly N, Anderson K, Freytes CO, Hildebrandt GC, Holmberg L, Krem MM, Lee C, Lekakis L, Lazarus HM, Mian H, Murthy HS, Nathan S, Nishihori T, Parrondo R, Patel SS, Solh M, Strouse C, Vesole DH, Kumar S, Qazilbash MH, Shah N, D'Souza A, Sidana S. Impact of bortezomib-based versus lenalidomide maintenance therapy on outcomes of patients with high-risk multiple myeloma. Cancer. 2023 Jul 15;129(14):2179-2191. doi: 10.1002/cncr.34778. PMID: 37021929.
12. Miljkovic M, Seguin A, Jia X, Cox JE, Catrow JL, Bergonia H, Phillips JD, Stephens WZ, Ward DM. Loss of the mitochondrial protein Abcb10 results in altered arginine metabolism in MEL and K562 cells and nutrient stress signaling through ATF4. J Biol Chem. 2023 Jul;299(7):104877. doi: 10.1016/j.jbc.2023.104877. PMID: 37269954; PMCID: PMC10316008.
13. Johnson PC, Woyach JA, Ulrich A, Marcotte V, Nipp RD, Lage DE, Nelson AM, Newcomb RA, Rice J, Lavoie MW, Ritchie CS, Bartlett N, Stephens DM, Ding W, Owen C, Stone R, Ruppert AS, Mandrekar SJ, Byrd JC, El-Jawahri A, Le-Rademacher J, Rosko A. Geriatric assessment measures are predictive of outcomes in chronic lymphocytic leukemia. J Geriatr Oncol. 2023 Jul;14(6):101538. doi: 10.1016/j.jgo.2023.101538. PMID: 37329769.
14. Ghimire B, Pour SK, Middleton E, Campbell RA, Nies MA, Aghazadeh-Habashi A. Renin-Angiotensin System Components and Arachidonic Acid Metabolites as Biomarkers of COVID-19. Biomedicines. 2023 Jul 27;11(8):2118. doi: 10.3390/biomedicines11082118. PMID: 37626615; PMCID: PMC10452267.
AUGUST
15. Morra A, Schreurs MAC, Andrulis IL, Anton-Culver H, Augustinsson A, Beckmann MW, Behrens S, Bojesen SE, Bolla MK, Brauch H, Broeks A, Buys SS, Camp NJ, Castelao JE, Cessna MH, Chang-Claude J, Chung WK; NBCS Collaborators; Colonna SV, Couch FJ, Cox A, Cross SS, Czene K, Daly MB, Dennis J, Devilee P, Dörk T, Dunning AM, Dwek M, Easton DF, Eccles DM, Eriksson M, Evans DG, Fasching PA, Fehm TN, Figueroa JD, Flyger H, Gabrielson M, Gago-Dominguez M, García-Closas M, García-Sáenz JA, Genkinger J, Grassmann F, Gündert M, Hahnen E, Haiman CA, Hamann U, Harrington PA, Hartikainen JM, Hoppe R, Hopper JL, Houlston RS, Howell A; ABCTB Investigators; kConFab Investigators; Jakubowska A, Janni W, Jernström H, John EM, Johnson N, Jones ME, Kristensen VN, Kurian AW, Lambrechts D, Le Marchand L, Lindblom A, Lubiński J, Lux MP, Mannermaa A, Mavroudis D, Mulligan AM, Muranen TA, Nevanlinna H, Nevelsteen I, Neven P, Newman WG, Obi N, Offit K, Olshan AF, Park-Simon TW, Patel AV, Peterlongo P, Phillips KA, Plaseska-Karanfilska D, Polley EC, Presneau N, Pylkäs K, Rack B, Radice P, Rashid MU, Rhenius V, Robson M, Romero A, Saloustros E, Sawyer EJ, Schmutzler RK, Schuetze S, Scott C, Shah M, Smichkoska S, Southey MC, Tapper WJ, Teras LR, Tollenaar RAEM, Tomczyk K, Tomlinson I, Troester MA, Vachon CM, van Veen EM, Wang Q, Wendt C, Wildiers H, Winqvist R, Ziogas A, Hall P, Pharoah PDP, Adank MA, Hollestelle A, Schmidt MK, Hooning MJ. Association of the CHEK2 c.1100delC variant, radiotherapy, and systemic treatment with contralateral breast cancer risk and breast cancer-specific survival. Cancer Med. 2023 Aug;12(15):16142-16162. doi: 10.1002/cam4.6272. PMID: 37401034; PMCID: PMC10469654.
16. Major A, Yu J, Shukla N, Che Y, Karrison TG, Treitman R, Kamdar MK, Haverkos BM, Godfrey J, Babcook MA, Voorhees TJ, Carlson S, Gaut D, Oliai C, Romancik JT, Winter AM, Hill BT, Bansal R, Villasboas Bisneto JC, Nizamuddin IA, Karmali R, Fitzgerald LA, Stephens DM, Pophali PA, Trabolsi A, Schatz JH, Hu M, Bachanova V, Slade MJ, Singh N, Ahmed N, McGuirk JP, Bishop MR, Riedell PA, Kline J. Efficacy of checkpoint inhibition after CAR-T failure in aggressive B-cell lymphomas: outcomes from 15 US institutions. Blood Adv. 2023 Aug 22;7(16):4528-4538. doi: 10.1182/bloodadvances.2023010016. PMID: 37026796; PMCID: PMC10425681.
17. Burningham Z, Jackson GL, Kelleher JL, Morris I, Stevens MB, Cohen J, Maloney G, Sauer BC, Halwani AS, Chen W, Vaughan CP. Use of a Medication Safety Audit and Feedback Tool in the Emergency Department Is Affected by Prescribing Characteristics. Appl Clin Inform. 2023 Aug;14(4):684-692. doi: 10.1055/s-0043-1771393. PMID: 37648222; PMCID: PMC10468720.
18. Booth CM, Sengar M, Goodman A, Wilson B, Aggarwal A, Berry S, Collingridge D, Denburg A, Eisenhauer EA, Ginsburg O, Goldstein D, Gunasekera S, Hammad N, Honda K, Jackson C, Karikios D, Knopf K, Koven R, Marini BL, Maskens D, Moraes FY, Mohyuddin GR, Poudyal BS, Pramesh CS, Roitberg F, Rubagumya F, Schott S, Sirohi B, Soto-Perez-de-Celis E, Sullivan R, Tannock IF, Trapani D, Tregear M, van der Graaf W, Vanderpuye V, Gyawali B. Common Sense Oncology: outcomes that matter. Lancet Oncol. 2023 Aug;24(8):833-835. doi: 10.1016/S1470-2045(23)00319-4. PMID: 37467768.
19. Chakraborty R, Al Hadidi S, Cliff ERS, Mohyuddin GR. Is aggressive treatment of smoldering myeloma the path to curing myeloma? Blood Adv. 2023 Aug 8;7(15):3932-3935. doi: 10.1182/bloodadvances.2023009658. PMID: 37196639; PMCID: PMC10405196.
20. Mian A, Naqvi SAA, Ayaz A, Husnain M, Aljama MA, Mohyuddin GR, Koehn K, Mohan M, Bin Riaz I, Chakraborty R. Incidence of second primary malignancies in patients with multiple myeloma receiving anti-CD38 monoclonal antibodies: A systematic review and meta-analysis. Leuk Res. 2023 Aug;131:107324. doi: 10.1016/j.leukres.2023.107324. PMID: 37285641.
21. Zhang X, Song J, Shah BN, Han J, Hassan T, Miasniakova G, Sergueeva A, Nekhai S, Machado RF, Gladwin MT, Saraf SL, Prchal JT, Gordeuk VR. Gene expression changes in sickle cell reticulocytes and their clinical associations. Sci Rep. 2023 Aug 8;13(1):12864. doi: 10.1038/s41598-023-40039-2. PMID: 37553354; PMCID: PMC10409856.
22. Song J, Sundar KM, Horvathova M, Gangaraju R, Indrak K, Christensen RD, Genzor S, Lundby C, Divoky V, Ganz T, Prchal JT. Increased blood reactive oxygen species and hepcidin in obstructive sleep apnea precludes expected erythrocytosis. Am J Hematol. 2023 Aug;98(8):1265-1276. doi: 10.1002/ajh.26992. PMID: 37350302.
23. Ferreri CJ, Hildebrandt MAT, Hashmi H, Shune LO, McGuirk JP, Sborov DW, Wagner CB, Kocoglu MH, Rapoport A, Atrash S, Voorhees PM, Khouri J, Dima D, Afrough A, Kaur G, Anderson LD Jr, Simmons G, Davis JA, Kalariya N, Peres LC, Lin Y, Janakiram M, Nadeem O, Alsina M, Locke FL, Sidana S, Hansen DK, Patel KK, Castaneda Puglianini OA. Real-world experience of patients with multiple myeloma receiving ide-cel after a prior BCMA-targeted therapy. Blood Cancer J. 2023 Aug 9;13(1):117. doi: 10.1038/s41408-023-00886-8. PMID: 37558706; PMCID: PMC10412575.
24. Kangro K, Campbell RA, Tilvawala R, Flick MJ, Wolberg AS. Citrullination of α2-antiplasmin is unlikely to contribute to enhanced plasmin generation in COVID-19 pathophysiology. Res Pract Thromb Haemost. 2023 Aug 30;7(6):102195. doi: 10.1016/j.rpth.2023.102195. PMID: 37736033; PMCID: PMC10510058.
25. Trunk AD, Patel SS, Prchal JT, Sborov DW, Zander AR, Lee CJ. Allogeneic stem cell transplant for multiple myeloma & myelofibrosis with split-dose busulfan, fludarabine & cyclophosphamide. Leuk Res Rep. 2023 Aug 26;20:100388. doi: 10.1016/j.lrr.2023.100388. PMID: 37701906; PMCID: PMC10493243.
26. Zinter MS, Brazauskas R, Strom J, Chen S, Bo-Subait S, Sharma A, Beitinjaneh A, Dimitrova D, Guilcher G, Preussler J, Myers K, Bhatt NS, Ringden O, Hematti P, Hayashi RJ, Patel S, De Oliveira SN, Rotz S, Badawy SM, Nishihori T, Buchbinder D, Hamilton B, Savani B, Schoemans H, Sorror M, Winestone L, Duncan C, Phelan R, Dvorak CC. Critical Illness Risk and Long-Term Outcomes Following Intensive Care in Pediatric Hematopoietic Cell Transplant Recipients. medRxiv [Preprint]. 2023 Aug 5:2023.07.31.23293444. doi: 10.1101/2023.07.31.23293444. PMID: 37577706; PMCID: PMC10418579.
SEPTEMBER
27. Davis JA, Sborov DW, Wesson W, Julian K, Abdallah AO, McGuirk JP, Ahmed N, Hashmi H. Efficacy and Safety of CD34+ Stem Cell Boost for Delayed Hematopoietic Recovery After BCMA Directed CAR T-cell Therapy. Transplant Cell Ther. 2023 Sep;29(9):567-571. doi: 10.1016/j.jtct.2023.05.012. PMID: 37225044.
28. Zhang X, Song J, Shah BN, Han J, Hassan T, Miasniakova G, Sergueeva A, Nekhai S, Machado RF, Gladwin MT, Saraf SL, Prchal JT, Gordeuk VR. Publisher Correction: Gene expression changes in sickle cell reticulocytes and their clinical associations. Sci Rep. 2023 Sep 14;13(1):15225. doi: 10.1038/s41598-023-42020-5. Erratum for: Sci Rep. 2023 Aug 8;13(1):12864. PMID: 37709839; PMCID: PMC10502004.
29. Hentzen S, Meirson T, Koehn K, Goodman A, Chakraborty R, Sborov D, Rubinstein S, Mohyuddin GR. Attrition and withdrawal in multiple myeloma randomized controlled trials: A systematic review. Eur J Haematol. 2023 Sep;111(3):491-498. doi: 10.1111/ejh.14032. PMID: 37382045.
30. Ajanel A, Campbell RA, Denorme F. Platelet mitochondria: the mighty few. Curr Opin Hematol. 2023 Sep 1;30(5):167-174. doi: 10.1097/MOH.0000000000000772. PMID: 37459354.
31. Denorme F, Armstrong ND, Stoller ML, Portier I, Tugolukova EA, Tanner RM, Montenont E, Bhatlekar S, Cody M, Rustad JL, Ajanel A, Tolley ND, Murray DC, Boyle JL, Nieman MT, McKenzie SE, Yost CC, Lange LA, Cushman M, Irvin MR, Bray PF, Campbell RA. The predominant PAR4 variant in individuals of African ancestry worsens murine and human stroke outcomes. J Clin Invest. 2023 Sep 15;133(18):e169608. doi: 10.1172/JCI169608. PMID: 37471144; PMCID: PMC10503801.
32. Mohyuddin GR, Prasad V. Detecting Selection Bias in Observational Studies-When Interventions Work Too Fast. JAMA Intern Med. 2023 Sep 1;183(9):897-898. doi: 10.1001/jamainternmed.2023.2067. PMID: 37306983.
33. Liu J, Osman AEG, Bolton K, Godley LA. Germline predisposition to clonal hematopoiesis. Leuk Res. 2023 Sep;132:107344. doi: 10.1016/j.leukres.2023.107344. PMID: 37421681.
34. Parks AL, Fazili M, Aston V, Porter TF, Branch DW, Woller SC, Snow GL, Stevens SM. Excluding pregnancy-associated deep vein thrombosis with whole-leg ultrasound. Res Pract Thromb Haemost. 2023 Sep 14;7(7):102202. doi: 10.1016/j.rpth.2023.102202. PMID: 37840688; PMCID: PMC10569988.
OCTOBER
35. Berndt SI, Vijai J, Benavente Y, Camp NJ, Nieters A, Wang Z, Smedby KE, Kleinstern G, Hjalgrim H, Besson C, Skibola CF, Morton LM, Brooks-Wilson AR, Teras LR, Breeze C, Arias J, Adami HO, Albanes D, Anderson KC, Ansell SM, Bassig B, Becker N, Bhatti P, Birmann BM, Boffetta P, Bracci PM, Brennan P, Brown EE, Burdett L, Cannon-Albright LA, Chang ET, Chiu BCH, Chung CC, Clavel J, Cocco P, Colditz G, Conde L, Conti DV, Cox DG, Curtin K, Casabonne D, De Vivo I, Diepstra A, Diver WR, Dogan A, Edlund CK, Foretova L, Fraumeni JF Jr, Gabbas A, Ghesquières H, Giles GG, Glaser S, Glenn M, Glimelius B, Gu J, Habermann TM, Haiman CA, Haioun C, Hofmann JN, Holford TR, Holly EA, Hutchinson A, Izhar A, Jackson RD, Jarrett RF, Kaaks R, Kane E, Kolonel LN, Kong Y, Kraft P, Kricker A, Lake A, Lan Q, Lawrence C, Li D, Liebow M, Link BK, Magnani C, Maynadie M, McKay J, Melbye M, Miligi L, Milne RL, Molina TJ, Monnereau A, Montalvan R, North KE, Novak AJ, Onel K, Purdue MP, Rand KA, Riboli E, Riby J, Roman E, Salles G, Sborov DW, Severson RK, Shanafelt TD, Smith MT, Smith A, Song KW, Song L, Southey MC, Spinelli JJ, Staines A, Stephens D, Sutherland HJ, Tkachuk K, Thompson CA, Tilly H, Tinker LF, Travis RC, Turner J, Vachon CM, Vajdic CM, Van Den Berg A, Van Den Berg DJ, Vermeulen RCH, Vineis P, Wang SS, Weiderpass E, Weiner GJ, Weinstein S, Doo NW, Ye Y, Yeager M, Yu K, Zeleniuch-Jacquotte A, Zhang Y, Zheng T, Ziv E, Sampson J, Chatterjee N, Offit K, Cozen W, Wu X, Cerhan JR, Chanock SJ, Slager SL, Rothman N. Correction: Distinct germline genetic susceptibility profiles identified for common non-Hodgkin lymphoma subtypes. Leukemia. 2023 Oct;37(10):2142. doi: 10.1038/s41375-023-01978-x. Erratum for: Leukemia. 2022 Dec;36(12):2835-2844. PMID: 37666943.
36. Beechinor RJ, Mahmoudjafari Z, Mohyuddin GR. Financial Toxicity in Oncology, More Unanswered Questions. J Clin Oncol. 2023 Oct 1;41(28):4600-4601. doi: 10.1200/JCO.23.00915. PMID: 37459577.
37. Prchal JT, Semenza GL. On either side of homeostasis: EPAS1 gain- and loss-offunction mutations. Haematologica. 2023 Oct 1;108(10):2564-2565. doi: 10.3324/haematol.2023.283285. PMID: 37288511; PMCID: PMC10542834.
38. Reynolds G, Cliff ERS, Mohyuddin GR, Popat R, Midha S, Liet Hing MN, Harrison SJ, Kesselheim AS, Teh BW. Infections following bispecific antibodies in myeloma: a systematic review and meta-analysis. Blood Adv. 2023 Oct 10;7(19):5898-5903. doi: 10.1182/bloodadvances.2023010539. PMID: 37467036.
39. Shah BN, Zhang X, Sergueeva AI, Miasnikova GY, Ganz T, Prchal JT, Gordeuk VR. Increased transferrin protects from thrombosis in Chuvash erythrocytosis. Am J Hematol. 2023 Oct;98(10):1532-1539. doi: 10.1002/ajh.27021. PMID: 37435906; PMCID: PMC10529798.
40. Sindt JE, Fitzgerald LA, Kuznicki J, Prelewicz S, Odell DW, Brogan SE. Antiplatelet and Wound Healing Implications of Immunotherapy and Targeted Cancer Therapies in the Perioperative Period. Anesthesiology. 2023 Oct 1;139(4):511-522. doi: 10.1097/ALN.0000000000004669. PMID: 37698434.
41. de Jong CMM, de Wit K, Black SA, Gwozdz AM, Masias C, Parks AL, Robert-Ebadi H, Talerico R, Woller SC, Klok FA. Use of patient-reported outcome measures in patients with venous thromboembolism: communication from the ISTH SSC Subcommittee on Predictive and Diagnostic Variables in Thrombotic Disease. J Thromb Haemost. 2023 Oct;21(10):2953-2962. doi: 10.1016/j.jtha.2023.06.023. PMID: 37394119.
42. Parks AL, Stevens SM. In intermediate- or high-risk PE, catheter-directed thrombolysis is linked to reduced mortality vs. systemic thrombolysis or anticoagulation. Ann Intern Med. 2023 Oct;176(10):JC118. doi: 10.7326/J23-0076. Oct 3. PMID: 37782927.
43. Siebert AE, Brake MA, Verbeek SC, Johnston AJ, Morgan AP, Cleuren AC, Jurek AM, Schneider CD, Germain DM, Battistuzzi FU, Zhu G, Miller DR, Johnsen JM, Pardo-Manuel de Villena F, Rondina MT, Westrick RJ. Identification of genomic loci regulating platelet plasminogen activator inhibitor-1 in mice. J Thromb Haemost. 2023 Oct;21(10):2917-2928. doi: 10.1016/j.jtha.2023.06.018. PMID: 37364776.
44. Voorhees PM, Sborov DW, Laubach J, Kaufman JL, Reeves B, Rodriguez C, Chari A, Silbermann R, Costa LJ, Anderson LD Jr, Nathwani N, Shah N, Bumma N, Efebera YA, Holstein SA, Costello C, Jakubowiak A, Wildes TM, Orlowski RZ, Shain KH, Cowan AJ, Dinner S, Pei H, Cortoos A, Patel S, Lin TS, Usmani SZ, Richardson PG. Addition of daratumumab to lenalidomide, bortezomib, and dexamethasone for transplantation-eligible patients with newly diagnosed multiple myeloma (GRIFFIN): final analysis of an open-label, randomised, phase 2 trial. Lancet Haematol. 2023 Oct;10(10):e825-e837. doi: 10.1016/S2352-3026(23)00217-X. PMID: 37708911.
45. Denorme F, Campbell RA. Platelets net neutrophils during ALI. Blood. 2023 Oct 26;142(17):1409-1410. doi: 10.1182/blood.2023021641. PMID: 37883112.
46. Rasmussen KM, Patil V, Li C, Yong C, Appukkuttan S, Grossman JP, Jhaveri J, Halwani AS. Survival Outcomes by Race and Ethnicity in Veterans With Nonmetastatic Castration-Resistant Prostate Cancer. JAMA Netw Open. 2023 Oct 2;6(10):e2337272. doi: 10.1001/jamanetworkopen.2023.37272. Erratum in: JAMA Netw Open. 2023 Nov 1;6(11):e2343869. PMID: 37819658; PMCID: PMC10568364.
47. Jackson LK, Dailey TA, Anderle B, Warren MJ, Bergonia HA, Dailey HA, Phillips JD. Exploiting Differences in Heme Biosynthesis between Bacterial Species to Screen for Novel Antimicrobials. Biomolecules. 2023 Oct 6;13(10):1485. doi: 10.3390/biom13101485. PMID: 37892169; PMCID: PMC10604556.
48. Najjar M, McCarron J, Cliff ERS, Berger K, Steensma DP, Al Hadidi S, Chakraborty R, Goodman A, Anto E, Greene T, Sborov D, Mohyuddin GR. Adverse Event Reporting in Randomized Clinical Trials for Multiple Myeloma. JAMA Netw Open. 2023 Nov 1;6(11):e2342195. doi: 10.1001/jamanetworkopen.2023.42195. PMID: 37948080; PMCID: PMC10638643.
49. Pek RH, Yuan X, Rietzschel N, Zhang J, Jackson L, Nishibori E, Ribeiro A, Simmons W, Jagadeesh J, Sugimoto H, Alam MZ, Garrett L, Haldar M, Ralle M, Phillips JD, Bodine DM, Hamza I. Correction: Hemozoin produced by mammals confers heme tolerance. Elife. 2023 Oct 20;12:e93253. doi: 10.7554/eLife.93253. Erratum for: Elife. 2019 Oct 01;8: PMID: 37860965; PMCID: PMC10588980.
NOVEMBER
50. Dickey BL, Putney RM, Suneja G, Kresovich JK, Spivak AM, Patel AB, Teng M, Extermann M, Giuliano AR, Gillis N, Berglund A, Coghill AE. Differences in epigenetic age by HIV status among patients with a non-AIDS defining cancer. AIDS. 2023 Nov 1;37(13):2049-2057. doi: 10.1097/QAD.0000000000003661. PMID: 37467055; PMCID: PMC10538418.
51. Tashi T, Deininger MW. Management of Advanced Systemic Mastocytosis and Associated Myeloid Neoplasms. Immunol Allergy Clin North Am. 2023 Nov;43(4):723-741. doi: 10.1016/j.iac.2023.04.009. PMID: 37758409.
52. Mohyuddin GR, Meirson T. A critical appraisal of the ATLAS trial of maintenance therapy for multiple myeloma: end points, censoring and equipoise. Nat Rev Clin Oncol. 2023 Nov;20(11):735-736. doi: 10.1038/s41571-023-00801-x. PMID: 37433885.
53. Xiao X, Xu Y, Moschetta GA, Yu Y, Fisher AL, Alfaro-Magallanes VM, McMillen S, Phillips S, Wang CY, Christian J, Babitt JL. BMP5 contributes to hepcidin regulation and systemic iron homeostasis in mice. Blood. 2023 Oct 12;142(15):1312-1322. doi: 10.1182/blood.2022019195. PMID: 37478395; PMCID: PMC10613724.
54. Nersisyan S, Montenont E, Loher P, Middleton EA, Campbell R, Bray P, Rigoutsos I. Characterization of all small RNAs in and comparisons across cultured megakaryocytes and platelets of healthy individuals and COVID-19 patients. J Thromb Haemost. 2023 Nov;21(11):3252-3267. doi: 10.1016/j.jtha.2023.07.028. PMID: 37558133.
55. Bowers JT, Anna JL, Bair SM, Annunzio K, Epperla N, Joy Pullukkara J, Gaballa S, Spinner MA, Li S, Messmer MR, Nguyen JDK, Ayers EC, Wagner C, Hu B, Di M, Huntington SF, Furqan F, Shah NN, Chen C, Ballard HJ, Hughes ME, Chong EA, Nasta SD, Barta SK, Landsburg DJ, Svoboda J. Brentuximab vedotin plus AVD for Hodgkin lymphoma: incidence and management of peripheral neuropathy in a multisite cohort. Blood Adv. 2023 Nov 14;7(21):6630-6638. doi: 10.1182/bloodadvances.2023010622. PMID: 37595053.
56. Baljevic M, Sborov DW. Understanding risks and refining strategies for thromboembolism prophylaxis in hematopoietic stem cell transplant recipients. Bone Marrow Transplant. 2023 Nov;58(11):1177-1178. doi: 10.1038/s41409-023-02044-x. PMID: 37626266.
57. Denorme F, Andrianova I, Cody MJ, Kosaka Y, Campbell RA. Age Specific Impact of Type I Interferons on Cerebral Thrombosis and Inflammation. Blood Adv. 2023 Nov 14;7(21):6672-6675. doi: 10.1182/bloodadvances.2023010495. PMID: 37738163.
58. Wagner CB, Boucher K, Nedved A, Micallef IN, Desai S, Hatic H, Goyal G, Zacholski E, Fegley A, Sigmund AM, Bond DA, Samuels C, Kamdar MK, Ba Aqeel S, Torka P, MacDougall K, Borogovac A, Rajeeve S, Sundaram S, Fedak K, Modi D, Travers E, Ayyappan S, Chilakamarri N, Brem EA, Ermann DA, Fitzgerald LA, Hu B, Stephens DM, Shah H. Effect of cumulative dose of brentuximab vedotin maintenance in relapsed/refractory classical Hodgkin lymphoma after autologous stem cell transplant: an analysis of real-world outcomes. Haematologica. 2023 Nov 1;108(11):3025-3032. doi: 10.3324/haematol.2023.282780. PMID: 37102592; PMCID: PMC10620571.
59. Rondina MT. Targeting prostacyclin: all gain with no pain? Blood. 2023 Nov 2;142(18):1506-1507. doi: 10.1182/blood.2023022227. PMID: 37917084.
60. Petrocelli JJ, McKenzie AI, de Hart NMMP, Reidy PT, Mahmassani ZS, Keeble AR, Kaput KL, Wahl MP, Rondina MT, Marcus RL, Welt CK, Holland WL, Funai K, Fry CS, Drummond MJ. Disuse-induced muscle fibrosis, cellular senescence, and senescence-associated secretory phenotype in older adults are alleviated during re-ambulation with metformin pre-treatment. Aging Cell. 2023 Nov;22(11):e13936. doi: 10.1111/acel.13936. PMID: 37486024; PMCID: PMC10652302.
61. Levi H, Carmi S, Rosset S, Yerushalmi R, Zick A, Yablonski-Peretz T; BCAC Consortium; Wang Q, Bolla MK, Dennis J, Michailidou K, Lush M, Ahearn T, Andrulis IL, Anton-Culver H, Antoniou AC, Arndt V, Augustinsson A, Auvinen P, Beane Freeman L, Beckmann M, Behrens S, Bermisheva M, Bodelon C, Bogdanova NV, Bojesen SE, Brenner H, Byers H, Camp N, Castelao J, Chang-Claude J, Chirlaque MD, Chung W, Clarke C; NBCS Collaborators; Collee MJ, Colonna S; CTS Consortium; Couch F, Cox A, Cross SS, Czene K, Daly M, Devilee P, Dork T, Dossus L, Eccles DM, Eliassen AH, Eriksson M, Evans G, Fasching P, Fletcher O, Flyger H, Fritschi L, Gabrielson M, Gago-Dominguez M, García-Closas M, Garcia-Saenz JA, Genkinger J, Giles GG, Goldberg M, Guénel P, Hall P, Hamann U, He W, Hillemanns P, Hollestelle A, Hoppe R, Hopper J; ABCTB Investigators; Jakovchevska S, Jakubowska A, Jernström H, John E, Johnson N, Jones M, Vijai J, Kaaks R, Khusnutdinova E, Kitahara C, Koutros S, Kristensen V, Kurian AW, Lacey J, Lambrechts D, Le Marchand L, Lejbkowicz F, Lindblom A, Loibl S, Lori A, Lubinski J, Mannermaa A, Manoochehri M, Mavroudis D, Menon U, Mulligan A, Murphy R, Nevelsteen I, Newman WG, Obi N, O'Brien K, Offit K, Olshan A, Plaseska-Karanfilska D, Olson J, Panico S, Park-Simon TW, Patel A, Peterlongo P, Rack B, Radice P, Rennert G, Rhenius V, Romero A, Saloustros E, Sandler D, Schmidt MK, Schwentner L, Shah M, Sharma P, Simard J, Southey M, Stone J, Tapper WJ, Taylor J, Teras L, Toland AE, Troester M, Truong T, van der Kolk LE, Weinberg C, Wendt C, Yang XR, Zheng W, Ziogas A, Dunning AM, Pharoah P, Easton DF, Ben-Sachar S, Elefant N, Shamir R, Elkon R. Evaluation of European-based polygenic risk score for breast cancer in Ashkenazi Jewish women in Israel. J Med Genet. 2023 Nov 27;60(12):1186-1197. doi: 10.1136/jmg-2023-109185. PMID: 37451831.
62. Dobish KK, Wittorf KJ, Swenson SA, Bean DC, Gavile CM, Woods NT, Ghosal G, Hyde RK, Buckley SM. FBXO21 mediated degradation of p85α regulates proliferation and survival of acute myeloid leukemia. Leukemia. 2023 Nov;37(11):2197-2208. doi: 10.1038/s41375-023-02020-w. PMID: 37689825; PMCID: PMC10624613.
63. Macauda A, Briem K, Clay-Gilmour A, Cozen W, Försti A, Giaccherini M, Corradi C, Sainz J, Niazi Y, Ter Horst R, Li Y, Netea MG, Vogel U, Hemminki K, Slager SL, Varkonyi J, Andersen V, Iskierka-Jazdzewska E, Mártinez-Lopez J, Zaucha J, Camp NJ, Rajkumar SV, Druzd-Sitek A, Bhatti P, Chanock SJ, Kumar SK, Subocz E, Mazur G, Landi S, Machiela MJ, Jerez A, Norman AD, Hildebrandt MAT, Kadar K, Berndt SI, Ziv E, Buda G, Nagler A, Dumontet C, Raźny M, Watek M, Butrym A, Grzasko N, Dudzinski M, Rybicka-Ramos M, Matera EL, García-Sanz R, Goldschmidt H, Jamroziak K, Jurczyszyn A, Clavero E, Giles GG, Pelosini M, Zawirska D, Kruszewski M, Marques H, Haastrup E, Sánchez-Maldonado JM, Bertsch U, Rymko M, Raab MS, Brown EE, Hofmann JN, Vachon C, Campa D, Canzian F. Identification of novel genetic loci for risk of multiple myeloma by functional annotation. Leukemia. 2023 Nov;37(11):2326-2329. doi: 10.1038/s41375-023-02022 8. PMID: 37723249; PMCID: PMC10624610.
64. Murthy HS, Zhang MJ, Chen K, Ahmed S, Deotare U, Ganguly S, Kansagra A, Michelis FV, Nishihori T, Patnaik M, Abid MB, Aljurf M, Arai Y, Bacher U, Badar T, Badawy SM, Ballen K, Battiwalla M, Beitinjaneh A, Bejanyan N, Bhatt VR, Brown VI, Martino R, Cahn JY, Castillo P, Cerny J, Chhabra S, Copelan E, Daly A, Dholaria B, Diaz Perez MA, Freytes CO, Grunwald MR, Hashmi S, Hildebrandt GC, Jamy O, Joseph J, Kanakry CG, Khera N, Krem MM, Kuwatsuka Y, Lazarus HM, Lekakis LJ, Liu H, Modi D, Munshi PN, Mussetti A, Palmisiano N, Patel SS, Rizzieri DA, Seo S, Shah MV, Sharma A, Sohl M, Solomon SR, Ulrickson M, Ustun C, van der Poel M, Verdonck LF, Wagner JL, Wang T, Wirk B, Zeidan A, Litzow M, Kebriaei P, Hourigan CS, Weisdorf DJ, Saber W, Kharfan-Dabaja MA. Allogeneic hematopoietic cell transplantation for blastic plasmacytoid dendritic cell neoplasm: a CIBMTR analysis. Blood Adv. 2023 Nov 28;7(22):7007-7016. doi: 10.1182/bloodadvances.2023011308. PMID: 37792849.
65. Epperla N, Feng L, Shah NN, Fitzgerald L, Shah H, Stephens DM, Lee CJ, Ollila T, Shouse G, Danilov AV, David KA, Torka P, Hashmi H, Hess B, Barta SK, Romancik JT, Cohen JB, Annunzio K, Kittai AS, Reneau J, Zurko J, Nizamuddin IA, Winter JN, Gordon LI, Ma S, Patel R, Nastoupil L, Ahmed S, Karmali R. Outcomes of patients with secondary central nervous system lymphoma following CAR T-cell therapy: a multicenter cohort study. J Hematol Oncol. 2023 Nov 9;16(1):111. doi: 10.1186/s13045-023-01508-3. PMID: 37946255; PMCID: PMC10633964.
66. Zelenetz AD, Gordon LI, Abramson JS, Advani RH, Andreadis B, Bartlett NL, Budde LE, Caimi PF, Chang JE, Christian B, DeVos S, Dholaria B, Fayad LE, Habermann TM, Hamid MS, Hernandez-Ilizaliturri F, Hu B, Kaminski MS, Karimi Y, Kelsey CR, King R, Krivacic S, LaCasce AS, Lim M, Messmer M, Narkhede M, Rabinovitch R, Ramakrishnan P, Reid E, Roberts KB, Saeed H, Smith SD, Svoboda J, Swinnen LJ, Tuscano J, Vose JM, Dwyer MA, Sundar H. NCCN Guidelines® Insights: B-Cell Lymphomas, Version 6.2023. J Natl Compr Canc Netw. 2023 Nov;21(11):1118-1131. doi: 10.6004/jnccn.2023.0057. PMID: 37935098.
67. Rondina MT. Targeting prostacyclin: all gain with no pain? Blood. 2023 Nov 2;142(18):1506-1507. doi: 10.1182/blood.2023022227. PMID: 37917084.
DECEMBER
68. Yoo JJ, Cohen HJ, Artz AS, Price E, Fill JA, Prchal J, Sapp S, Barnhart H; from the Partnership for Anemia Clinical and Translational Trials in the Elderly (PACTTE). Biomarkers of erythropoiesis response to intravenous iron in a crossover pilot study in unexplained anemia of the elderly. Hematology. 2023 Dec;28(1):1-8. doi: 10.1080/16078454.2023.2204613. PMID: 37114660; PMCID: PMC10281558.
69. Nooka AK, Cohen AD, Lee HC, Badros A, Suvannasankha A, Callander N, Abdallah AO, Trudel S, Chari A, Libby EN, Chaudhry M, Hultcrantz M, Kortüm KM, Popat R, Sborov D, Hakim S, Lewis E, Gorsh B, Bhushan B, McKeown A, Gupta I, Opalinska J, Richardson PG, Lonial S. Single-agent belantamab mafodotin in patients with relapsed/refractory multiple myeloma: Final analysis of the DREAMM-2 trial. Cancer. 2023 Dec 1;129(23):3746-3760. doi: 10.1002/cncr.34987. PMID: 37622738.
70. McCurdy A, Seow H, Pond GP, Gayowsky A, Chakraborty R, Visram A, Kaedbey R, D'Souza A, Mohyuddin GR, Wildes TM, Fonseca R, Mian H. Cancer-specific mortality in multiple myeloma: a population-based retrospective cohort study. Haematologica. 2023 Dec 1;108(12):3384-3391. doi: 10.3324/haematol.2023.282905. PMID: 37439357.
71. Beechinor RJ, Mohyuddin GR, Mitchell DE, Aaron D, Mahmoudjafari Z. The story of the development of generic lenalidomide: How one company thwarted the Hatch-Waxman Act to generate billions of dollars in revenue. J Cancer Policy. 2023 Dec;38:100446. doi: 10.1016/j.jcpo.2023.100446. PMID: 37777010.
72. Wheeler AP, Lim MY, Huguelet PS, Jaffray J, Staber JM, Funkhouser K, Carpenter SL, Weyand AC. Trends in dedicated care for females with bleeding disorders within U.S. hemophilia treatment centers. Am J Hematol. 2023 Dec;98(12):E399-E402. doi: 10.1002/ajh.27115. PMID: 37800397.
TBD
73. Guo L, Jacob S, Manne BK, Kolawole EM, Guo S, Wang X, Murray D, Tugolukova EA, Portier I, Kosaka Y, Barba C, Rondina MT, Evavold B, Morley C, Bhatlekar S, Bray PF. Actin-bundling protein L-plastin promotes megakaryocyte rigidity and dampens proplatelet formation. Haematologica. 2023 Jul 13. doi: 10.3324/haematol.2023.283016. Epub ahead of print. PMID: 37439340.
74. Steinbach M, Neupane K, Aziz M, Lee-Smith W, Julian K, Godara A, McClune B, Kelkar AH, Sborov D, Mohyuddin GR. Multiple Myeloma in Young Patients: A Scoping Review. Clin Lymphoma Myeloma Leuk. 2023 Aug 28:S2152-2650(23)00277-X. doi: 10.1016/j.clml.2023.08.019. Epub ahead of print. PMID: 37722944.
75. Desai SH, Spinner MA, Evens AM, Sýkorová A, Bachanova V, Goyal G, Kahl BS, Dorritie KA, Azzi J, Kenkre VP, Chang C, Michalka J, Ansell SM, Fusco B, Sumransub N, Hatic H, Saba R, Ibrahim U, Harris EI, Shah HR, Wagner-Johnston ND, Arai S, Nowakowski GS, Mocikova H, Jagadeesh D, Blum K, Diefenbach C, Iyengar S, Rappazzo KC, Baidoun F, Choi Y, Prochazka V, Advani RH, Micallef IN. Overall survival of cHL patients who progress after autologous stem cell transplant: results in novel agent era. Blood Adv. 2023 Sep 20:bloodadvances.2023011205. doi: 10.1182/bloodadvances.2023011205. Epub ahead of print. PMID: 37729621.
76. Gomez-Lumbreras A, Mercadal Vilchez S, Villa-Zapata L, Malone DC, Couriel DR. Chimeric antigen receptor T-cell immunotherapies adverse events reported to FAERS database: focus on cytopenias. Leuk Lymphoma. 2023 Sep 14:1-10. doi: 10.1080/10428194.2023.2254430. Epub ahead of print. PMID: 37708442.
77. Bhatnagar B, Zhao Q, Mims AS, Vasu S, Behbehani GK, Larkin K, Blachly JS, Badawi MA, Hill KL, Dzwigalski KR, Phelps MA, Blum W, Klisovic RB, Ruppert AS, Ranganathan P, Walker AR, Garzon R. Phase 1 study of selinexor in combination with salvage chemotherapy in Adults with relapsed or refractory Acute myeloid leukemia. Leuk Lymphoma. 2023 Sep 4:1-10. doi: 10.1080/10428194.2023.2253480. Epub ahead of print. PMID: 37665178.
78. Sidana S, Peres LC, Hashmi H, Hosoya H, Ferreri C, Khouri J, Dima D, Atrash S, Voorhees P, Simmons G, Sborov DW, Kalariya N, Hovanky V, Bharadwaj S, Miklos D, Wagner C, Kocoglu MH, Kaur G, Davis JA, Midha S, Janakiram M, Freeman C, Alsina M, Locke F, Gonzalez R, Lin Y, McGuirk J, Afrough A, Shune L, Patel KK, Hansen DK. Idecabtagene vicleucel chimeric antigen receptor T-cell therapy for relapsed/refractory multiple myeloma with renal impairment. Haematologica. 2023 Sep 21. doi: 10.3324/haematol.2023.283940. Epub ahead of print. PMID: 37731379.
79. Byrnes JR, Lee TK, Sharaby S, Campbell RA, Dobson D, Holle LA, Luo M, Kangro K, Homeister J, Aleman MM, Luyendyk JP, Kerlin BA, Dumond JB, Wolberg AS. Reciprocal stabilization of coagulation factor XIII-A and -B subunits determines plasma FXIII concentration. Blood. 2023 Oct 26:blood.2023022042. doi: 10.1182/blood.2023022042. Epub ahead of print. PMID: 37883802.
80. Lee CJ, Wang T, Chen K, Arora M, Brazauskas R, Spellman SR, Kitko C, MacMillan ML, Pidala JA, Badawy SM, Bhatt N, Bhatt VR, DeFilipp Z, Diaz MA, Farhadfar N, Gadalla S, Hashmi S, Hematti P, Hossain NM, Inamoto Y, Lekakis LJ, Sharma A, Solomon S, Lee SJ, Couriel DR. Severity of Chronic Graft-versus-Host Disease and Late Effects Following Allogeneic Hematopoietic Cell Transplantation for Adults with Hematologic Malignancy. Transplant Cell Ther. 2023 Oct 14:S2666-6367(23)01614-7. doi: 10.1016/j.jtct.2023.10.010. Epub ahead of print. PMID: 37844687.
81. Odstrcil MS, Lee CJ, Sobieski C, Weisdorf D, Couriel D. Access to CAR T-cell therapy: Focus on diversity, equity and inclusion. Blood Rev. 2023 Oct 5:101136. doi: 10.1016/j.blre.2023.101136. Epub ahead of print. PMID: 37863793.
82. Hashmi H, Hansen DK, Peres LC, Puglianini OC, Freeman C, De Avila G, Sidana S, Shune L, Sborov DW, Davis J, Wagner C, Kocoglu MH, Atrash S, Voorhees P, Simmons G, Ferreri C, Kalariya N, Anderson LD Jr, Afrough A, Dima D, Khouri J, McGuirk J, Locke F, Baz R, Patel KK, Alsina M. Factors associated with refractoriness or early progression after idecabtagene vicleucel in patients with relapsed/refractory multiple myeloma: U.S. Myeloma Immunotherapy Consortium real world experience. Haematologica. 2023 Oct 19. doi: 10.3324/haematol.2023.283888. Epub ahead of print. PMID: 37855036.
83. Peres LC, Oswald LB, Dillard CM, De Avila G, Nishihori T, Blue BJ, Freeman CL, Locke FL, Alsina M, Castaneda Puglianini OA, Shune L, Sborov DW, Wagner C, Dima D, Hashmi H, Davis JA, Kocoglu MH, Badros AZ, Atrash S, Simmons G, Kalariya N, Ferreri CJ, Anderson LD Jr, Afrough A, Kaur G, Lin Y, Liu L, Nadeem O, Voorhees PM, Khouri J, McGuirk JP, Sidana S, Hansen DK, Patel KK. Racial and ethnic differences in clinical outcomes among multiple myeloma patients treated with CAR T-cell therapy. Blood Adv. 2023 Oct 16:bloodadvances.2023010894. doi: 10.1182/bloodadvances.2023010894. Epub ahead of print. PMID: 37855718.
84. Gambles MT, Sborov D, Shami P, Yang J, Kopeček J. Obinutuzumab-Based Drug-Free Macromolecular Therapeutics Synergizes with Topoisomerase Inhibitors. Macromol Biosci. 2023 Oct 15:e2300375. doi: 10.1002/mabi.202300375. Epub ahead of print. PMID: 37838941.
85. Portier I, Andrianova I, Campbell RA. Finding a fountain of youth in the blood. J Thromb Haemost. 2023 Nov 7:S1538-7836(23)00794-8. doi: 10.1016/j.jtha.2023.10.024. Epub ahead of print. PMID: 37940049.
86. Ermann DA, Vardell VA, Shah H, Fitzgerald L, Tao R, Gaffney DK, Stephens DM, Hu B. Survival Outcomes of Limited-Stage Diffuse Large B-Cell Lymphoma Treated With Radiation Therapy. Clin Lymphoma Myeloma Leuk. 2023 Oct 10:S2152-2650(23)01552-5. doi: 10.1016/j.clml.2023.09.006. Epub ahead of print. PMID: 38000981.
87. Azim A, Hu B, Gilligan S, Sarwal A, Hartsell S, Pandya V, Raphael KL. How I Evaluate a High Anion Gap Metabolic Acidosis. Clin J Am Soc Nephrol. 2023 Nov 17. doi: 10.2215/CJN.0000000000000381. Epub ahead of print. PMID: 37976122.
88. Alrawabdeh J, Alzu'bi M, Alzyoud M, Odeh N, Hamadneh Y, Mian H, Mohyuddin GR, Kelkar AH, Goodman AM, Chakraborty R, Russler-Germain DA, Mehra N, Baggio D, Scheffer Cliff ER, Al Hadidi S. Characteristics of Post-hoc Subgroup Analyses of Oncology Clinical Trials: A Systematic Review. JNCI Cancer Spectr. 2023 Nov 25:pkad100. doi: 10.1093/jncics/pkad100. Epub ahead of print. PMID: 38006333.
89. Prchal JT, Lichtman MA. Measurement of red cell, plasma, and blood volume: A perspective. Am J Hematol. 2023 Nov 15. doi: 10.1002/ajh.27158. Epub ahead of print. PMID: 37966977.
Current Fellow’s Accomplishment Highlights
Chris Nevala-Plagemann, MD/ PGY5
Chris is a second-year fellow who works closely with his mentor, Dr. Garrido-Laguna, on a number of projects with a GI oncology focus. Chris has presented abstracts utilizing real-world data in collaboration with Flatiron Health at both ASCO GI 2019 and 2020, and most recently presented work at ASCO 2020 entitled “Real-world outcomes of patients with BRAF mutated mCRC treated in the United States.” He wrote a review article in Nature Reviews Clinical Oncology entitled “From State-Of-The-Art Treatments to Novel Therapies for Advanced-Stage Pancreatic Cancer” which was published in 2020. For his second year of fellowship, Chris has enrolled in the Masters of Science Clinical Investigation program and his future research will focus on evaluating at the impact of the gut microbiome on treatment outcomes in pancreatic cancer using stool samples collected from newly diagnosed PDAC patients.
William “Bill” McKean, MD, PhD/ PGY5
Bill is a third-year fellow (who did an expedited residency through the MD/PhD PSTP program) who works in the lab of Dr. Jared Rutter. He is interested in neuro-oncology and plans to single board in medical oncology. His research involves understanding the metabolic dependencies of adult neural stem cells. Specifically, he is interested in how pyruvate transport and lactate formation influence the differentiation of neurons and glial cells. These findings will have direct implications toward treatment of aggressive tumors like glioblastoma and astrocytoma. They will also provide greater insight into cancer stem cells, resistant progenitor subpopulations within these neoplasms.
Charles Goodwin, MD PhD PGY6
Charles is a third-year fellow who works in the lab of Dr. Ryan O’Connell. Charles’ research specifically focuses on dysregulated metabolism in acute myeloid leukemia and metabolic interactions between leukemic blasts and the immune cells of the bone marrow tumor microenvironment. He and his lab hope to identify therapeutic targets in metabolic pathways that directly kill leukemic blasts while simultaneously enhancing anti-leukemic immune responses in the bone marrow tumor microenvironment. They are particularly interested in fatty acid metabolism as a promising target.
Eric Johnson, MD PGY6
Eric is a third-year and has been involved in a number of projects throughout fellowship, but more specifically he worked on a quality improvement-based project at the VA where he holds his continuity clinic. In order to help minimize skeletal-related events and pain complications from metastatic prostate cancer, he created a “bone-modifying agents’ guideline” utilizing the current status of the veteran’s prostate cancer and FRAX score. In doing so, he created an order set algorithm to guide physician’s choice of bone modifying agents.
Lindsey Fitzgerald, MD PGY6
Lindsey is a third-year fellow who works closely with her mentors in the lymphoma group (Drs. Martha Glenn, Debbie Stephens, and Boyu Hu) on a number of ongoing research projects. Recently, she had an abstract accepted at ASCO 2020 in which she performed a multi-institutional retrospective analysis of elderly patients (age over 70) across 5 US academic institutions who were treated with commercial CAR-T cell therapy for relapsed/refractory DLBCL to evaluate efficacy and toxicity outcomes. For her work, she was awarded the "Conquer Cancer - Loxo Oncology Endowed Merit Award" for one of the best abstracts submitted by a trainee in oncology.
Additionally, Lindsey was accepted into an externship in the National Cancer Institute's Cancer Therapy Evaluation Program (CTEP) near Washington, D.C. in October 2019. She served in the investigational drug branch (IDB) which oversees the early development and clinical application of novel therapeutics by collaborating with academia and industry. She reviewed letters of intent (LOIs) from top academic oncology investigators across the country, presented these LOIs to select committees with analysis of pros and cons for funding considerations, sat in on meetings with pharmaceutical companies, and learned the components of a successful LOI to make a clinical trial a reality.
Former Fellow’s Accomplishment Highlights
Katie Kerrigan, DO (class of 2020)
Katie was our former chief fellow from 2019-2020 and stayed on as Huntsman Cancer Institute faculty where she subspecializes in thoracic and head & neck oncology. Under the mentorship of Drs. Wallace Akeley and Shiven Patel, Katie performed a number of real-world research projects in collaboration with Flatiron Health. Two of her real-world NSCLC outcomes projects were presented at World Conference on Lung Cancer 2019 in Barcelona. Additionally, she performed a pilot study entitled “Prognostic Significance of Patient-Reported Outcomes in Cancer” which was published in the Journal of Oncology Practice in 2020. She was awarded the Joseph M. Quagliana award in September 2019 which provided financial support for her research. Katie plans to continue to study PROs in her practice and hopes to become a clinical investigator.
Benjamin Solomon, MD (class of 2019)
Ben was our former chief fellow from 2018-2019 and stayed on as Huntsman Cancer Institute faculty where he sees general oncology patients at our satellite clinic in Jackson, WY and subspecializes in GI oncology. Under the mentorship of Dr. Garrido-Laguna, Ben applied for and was accepted into the American Society of Clinical Oncology/American Association for Cancer Research Methods in Clinical Cancer Research Workshop, Vail, CO after his first year of fellowship. During the Vail workshop, he developed and wrote a protocol entitled “A phase I trial to assess the safety and preliminary efficacy of FOLFOX combined with nivolumab and a TIGIT inhibitor (BMS-986207) in advanced gastrointestinal malignancies.”
Justin Moser, MD (class of 2019)
Justin was very involved in clinical and real-world outcomes research with a specific emphasis on melanoma during his fellowship. He worked with numerous mentors including Drs. Grossman and Hu-Lieskovan from the melanoma group. His work has been both published and presented at a number of national (GI ASCO 2019) and international meetings (ESMO 2019), with his ESMO 2019 presentation entitled “Comparative-effectiveness of pembrolizumab versus nivolumab for patients with metastatic melanoma.” After graduation, Justin took an oncology position at HonorHealth in Scottsdale, AZ where he serves as an assistant professor and drug development scholar.
David Gill, MD (class of 2019)
David was heavily involved in GU oncology research during his residency at the University of Utah and fellowship at Huntsman Cancer Institute under the mentorship of Dr. Neeraj Agarwal. David has many publications in peer-reviewed journals discussing immunotherapy in RCC and in urothelial cancer, evaluating predictive biomarkers for responsiveness to VEGF inhibition in RCC, and in evaluating germline variants in prostate cancer which may be predictive to certain therapies. During his fellowship, he was awarded the Joseph M. Quagliana award in 2018. David single-boarded in medical oncology and graduated after two years of fellowship. He now practices at Intermountain Medical Center in Murray, UT and is their Director of GU Oncology.
Ami Patel, MD (class of 2017)
Ami Patel published two papers in 2016 on her research with Drs. Mike Deininger and Tom O'Hare. Her research focuses on the resistance of chronic myeloid leukemia to tyrosine kinase inhibitors (TKIs). She reported that inhibition of the STAT3 transcription factor blocks one mechanism of TKI resistance. This work published in Chem Med Chem highlights the potential therapeutic advantage of combinatorial treatment of CML. She published a first-author review on new strategies for therapy of BCR-ABL1-negative myeloproliferative neoplasms. This appeared in Clin Cancer Res in March of this year.
Sabarinath Venniyil Radhakrishnan, MBBS (class of 2016)
Sabarinath Radhakrishnan published a review article in the Br J Haematol on chimeric antigen receptor (CAR) therapy for multiple myeloma. Sabarinath's research with Drs. D. Atanackovic and T. Leutkens focuses on generating new CAR T cells therapies for multiple myeloma therapy. He is making excellent progress on a new antigen for CAR therapy.
